Patents by Inventor Frederick M. Enright
Frederick M. Enright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120297493Abstract: Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human.Type: ApplicationFiled: July 31, 2012Publication date: November 22, 2012Applicants: TransGenRx, Inc., The Board of Supervisors of Louisiana State Univ. and Agricultural and Mechanical CollegeInventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
-
Patent number: 8258100Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: June 19, 2009Date of Patent: September 4, 2012Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Patent number: 8236294Abstract: Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human.Type: GrantFiled: November 8, 2010Date of Patent: August 7, 2012Assignees: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, TransGenRx, Inc.Inventors: Richard K. Cooper, Frederick M. Enright, William C. Fioretti
-
Patent number: 8071364Abstract: Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human.Type: GrantFiled: December 24, 2004Date of Patent: December 6, 2011Assignees: TransGenRx, Inc., The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
-
Publication number: 20110162096Abstract: Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or humanType: ApplicationFiled: November 8, 2010Publication date: June 30, 2011Applicants: College, TransGenRx, Inc.Inventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
-
Publication number: 20100199366Abstract: Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human.Type: ApplicationFiled: December 24, 2004Publication date: August 5, 2010Inventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
-
Publication number: 20100016227Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: ApplicationFiled: June 19, 2009Publication date: January 21, 2010Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHNICAL COLLEGEInventors: FREDERICK M. ENRIGHT, JESSE M. JAYNES, WILLIAM HANSEL, KENNETH L. KOONCE, SAMUEL M. MCCANN, WEN H. YU, PATRICIA A. MELROSE, LANE D. FOIL, PHILIP H. ELZER
-
Patent number: 7566777Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: July 11, 2003Date of Patent: July 28, 2009Assignee: Board of Supervisors of Louisana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Publication number: 20090047235Abstract: A paratransgenesis system is disclosed to kill targeted social insects such as termites and cockroaches, for example the Formosan subterranean termite. A genetically modified yeast can be effectively used to express and deliver lytic peptides directly within the termite gut. Some highly lytic peptides directly damage the insect gut itself, leading to the death of the insect within about three days. Other lytic peptides kill all (or at least most) species of protozoa in the termite gut. The protozoa provide wood-digesting enzymes (cellulases) to the termite. Without these protozoa (and their cellulases) the insect dies within about six weeks. The system is completely free from conventional neurotoxins and other organic pesticides.Type: ApplicationFiled: May 15, 2008Publication date: February 19, 2009Inventors: Claudia R. Husseneder, James A. Ottea, Lane D. Foil, Frederick M. Enright, Richard K. Cooper
-
Patent number: 7262163Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% ?,?-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar ?,?-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.Type: GrantFiled: April 14, 2003Date of Patent: August 28, 2007Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer
-
Publication number: 20040059088Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% &agr;,&agr;-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar &agr;,&agr;-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.Type: ApplicationFiled: April 14, 2003Publication date: March 25, 2004Inventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer
-
Publication number: 20040018967Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: ApplicationFiled: July 11, 2003Publication date: January 29, 2004Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Patent number: 6680058Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components—the ligand and the lytic peptide—may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.Type: GrantFiled: February 22, 2000Date of Patent: January 20, 2004Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Patricia A. Melrose, Philip H. Elzer
-
Patent number: 6635740Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: September 24, 1999Date of Patent: October 21, 2003Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Patent number: 6566334Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% &agr;,&agr;-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar &agr;,&agr;-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.Type: GrantFiled: February 5, 1998Date of Patent: May 20, 2003Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer
-
Patent number: 6303568Abstract: A novel class of antimicrobial agents for animal species including cecropins, attacins, lysozymes, phage derived polypeptides, such as those transcribed from gene 13 of phage 22, an S protein from lambda phage, and an E protein from phage PhiXl74, as well as, synthetically derived polypeptides of similar nature. The antimicrobial agents can be used to treat microbial infections and as components of medicinal compositions. The genes encoding for such antimicrobial agents can be used to transform animal cells, especially embryonic cells. The transformed animals including such antimicrobial cells are also included.Type: GrantFiled: November 14, 1996Date of Patent: October 16, 2001Assignee: Helix Biomedix, Inc.Inventors: Jesse M. Jaynes, Frederick M. Enright, Kenneth L. White
-
Patent number: 6264952Abstract: Vaccines against facultative intracellular pathogens are disclosed. A host is vaccinated with non-viable but metabolically active agents. The non-viable agents produce immunogenic components that elicit protective host immune responses, with minimal likelihood of host infection by the vaccine agent. Living agents, either attenuated or virulent, are exposed to a dose of gamma irradiation (or other strong mutagen) that is sufficient to limit or prevent the replication of the agents within the host, but that is insufficient to stop the metabolic activities of the agent. In vitro exposure of a microbial agent to the damaging effects of gamma irradiation or of another strong mutagen induces certain stress responses in the infectious agent. These stress responses are similar to the stress responses that the virulent agent would produce within the tissues of the host.Type: GrantFiled: December 11, 1997Date of Patent: July 24, 2001Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Virginia Polytechnic Institute and State University, Board of Regents for Oklahoma State University, Cornell Research Foundation, Inc.Inventors: Frederick M. Enright, Alexander J. Winter, Gerhardt G. Schurig, John H. Wyckoff, III
-
Patent number: 6156568Abstract: Novel means have been discovered for increasing the resistance of an animal host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. The infection treated may, for example, be equine infectious anemia, or infection by the human immunodeficiency virus. Novel means have also been found for treating tumors. Augmentation of the host's defenses against infectious diseases or tumors is achieved by "arming" the host's cells with an exogenous gene encoding a natural or synthetic lytic peptide. For example, the transfection of hematopoietic stem cells and embryonic cells will produce animals with enhanced disease resistance; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors. Genes coding for a cecropin or other native or synthetic lytic peptide can be transferred and stably expressed in mammalian, bony fish, other vertebrate, and other animal cells.Type: GrantFiled: July 16, 1997Date of Patent: December 5, 2000Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Richard K. Cooper, Frederick M. Enright
-
Patent number: 5998698Abstract: Novel means have been discovered for increasing the resistance of an animal host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. The infection treated may, for example, be equine infectious anemia, or infection by the human immunodeficiency virus. Novel means have also been found for treating tumors Augmentation of the host's defenses against infectious diseases or tumors is achieved by "arming" the host's cells with an exogenous gene encoding a natural or synthetic lytic peptide. For example, the transfection of hematopoietic stem cells and embryonic cells will produce animals with enhanced disease resistance; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors. Genes coding for a cecropin or other native or synthetic lytic peptide can be transferred and stably expressed in mammalian, bony fish, other vertebrate, and other animal cells.Type: GrantFiled: June 7, 1995Date of Patent: December 7, 1999Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Richard K. Cooper, Frederick M. Enright
-
Patent number: 5556782Abstract: Novel means have been discovered for increasing the resistance of a mammalian host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. Novel means have also been found for treating tumors. Augmentation of the host's defenses against infectious diseases or tumors is achieved by "arming" the host's cells with a gene encoding the lytic peptide cecropin B. The host's own leukocytes, other cells involved in resistance to infection, or other cells are transformed, and expression of the gene is induced when needed to combat pathogens. Transfection of hematopoietic stem cells with the cecropin B gene will enhance disease resistance in mammals; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors.Type: GrantFiled: May 25, 1995Date of Patent: September 17, 1996Assignee: Board of Supervisors of Louisiana State University and Agricultural & Mechanical CollegeInventors: Richard K. Cooper, Frederick M. Enright